Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Apoptotic tumor cell-derived microparticles loading Napabucasin inhibit CSCs and synergistic immune therapy

Fig. 5

In vivo PET/CT imaging and biodistribution of CT26 tumor-bearing mice. A PET/CT images of CT26 tumor-bearing mice after tail vein injection of N3-TMPs@NAP (i.v.) for 20 h, and intravenous injection of 68 Ga-L-NETA-DBCO for 1 h, 2 h. B PET/CT images of CT26 tumor-bearing mice after oral administration of N3-TMPs@NAP (p.o.) for 20 h, and intravenous injection of 68 Ga-L-NETA-DBCO for 1 h, 2 h. C Tissues uptakes of CT26 tumor-bearing mice at 2 h after the injection of 68 Ga-L-NETA-DBCO. D–E Tumor uptake and tumor to muscle uptake ratio at 2 h after the injection of.68 Ga-L-NETA-DBCO. F Fluorescence images of tumor tissues after i.v. or p.o. of Cy5/N3-TMPs@NAP. Scale bars = 200 μm. Data are represented as mean ± SD (n = 3; *P < 0.05; **P < 0.01; ***P < 0.001)

Back to article page